Contact our breast care nurses 0808 800 6000

Breast Cancer Now media statements

113 results
Media Statement
We respond to NICE decision to recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to the good news that the National Institute for Health and Care Excellence decided to recommend tucatinib with trastuzumab and capecitabine, for routine use on the NHS.

25 Feb 2022

Media Statement
We respond to today's NHSE Breast Screening Programme 2020-21 report

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to NHS England Breast Screening Programme 2020 to 2021 report.

24 Feb 2022

Media Statement
We respond to the latest COVID-19 guidance

Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, has expressed deep disappointment about the latest COVID-19 guidance.

22 Feb 2022

Media Statement
We respond to a new study looking at breast pain and breast cancer

Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, responded to a new study looking at breast pain and breast cancer.

22 Feb 2022

Media Statement
We respond to 'The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation’

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to new research about the projected impact of the COVID-19 lockdown on breast cancer deaths in England.

15 Feb 2022

Media Statement
We respond to NHS England breast cancer waiting times: December 2021

Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, commented on NHS England breast cancer waiting times for December 2021.

10 Feb 2022

Media Statement
Responding to new research that pembrolizumab cuts the risk of triple negative breast cancer returning by 37%

Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, responded to new research which shows pembrolizumab cuts the risk of triple negative breast cancer returning by 37%.

10 Feb 2022

Media Statement
We respond to House of Commons library analysis revealing record numbers of women facing delays to see an NHS cancer specialist

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, has commented on analysis that revealed record numbers of women facing delays to see an NHS cancer specialist - calling it alarming.

07 Feb 2022

Media Statement
We respond to Professor Gilbert’s talk at UK Interdisciplinary Breast Cancer Symposium, surrounding ‘Personalised breast cancer screening’

Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, responded to Professor Gilbert’s talk at the UK Interdisciplinary Breast Cancer Symposium.

31 Jan 2022

Media Statement
Responding to a new AI tool being tested to establish HER2 status in breast cancer

Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, has welcomed a new artificial intelligence (AI) tool that is being tested to establish HER2 status in breast cancer.

19 Jan 2022

Media Statement
We welcome the SMC’s approval of two new treatments for use on the NHS in Scotland- trastuzumab deruxtecan (Enhertu) and tucatinib (Tukysa) in combination with trastuzumab and capecitabine

Baroness Delyth Morgan, Breast Cancer Now’s Chief Executive, said the Scottish Medicines Consortium's approval of two new treatments for use on the NHS in Scotland marks an important leap forward.

17 Jan 2022

Media Statement
We respond to NHS England breast cancer waiting times: November 2021

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, commented on NHS England breast cancer waiting times for November 2021.

13 Jan 2022